03Aug 2022
TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer

TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer

To assess feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle‐invasive bladder cancer. Phase I data demonstrate it is feasible and safe to add cetuximab to chemoradiotherapy. Exploratory analysis of phase II data provides evidence to consider further clinical evaluation of cetuximab in this setting.

  • #urology

Like

Save

Share